Leerink Partners Starts Trillium Therapeutics (TRIL) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
UPDATE: Cowen Starts Trillium Therapeutics (TRIL) at Outperform
April 27, 2015 8:19 AM EDT(Updated - April 27, 2015 10:02 AM EDT)
Cowen initiated coverage on Trillium Therapeutics (NASDAQ: TRIL) with an Outperform rating. Analyst Boris Peaker sees potential in the company's novel SIRPaFc molecule.
"Trillium Therapeutics is an early-stage biotechnology company whose lead asset, SIRPaFc is a novel... More
Trillium Therapeutics (TRIL) Gains as Cohen's Point72 Asset Shows New 5.6% Stake
April 23, 2015 5:08 PM EDTMomentum stock Trillium Therapeutics (NASDAQ: TRIL) is gaining after the close (+5.9%) after Steven Cohen's family office Point72 Asset Management, L.P. (formerly SAC Capital) disclosed a 5.6%, or 378,050 share, stake in the company. The firm did not hold shares... More
